L-649923

L-649923 is an orally active CysLT1 antagonist. L-649923 reduced the incidence of gastritis in an animal model of acute gastric mucosal injury. L-649923 can be used in research on diseases such as asthma and gastritis[1][2].

Product Specifications

CAS Number

[114370-57-9]

UNSPSC

12352005

Target

Leukotriene Receptor

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

OC(C[C@H](C)[C@@H](O)C(C=C1)=CC=C1SCCCOC2=C(C(O)=C(C(C)=O)C=C2)CCC)=O

Molecular Formula

C25H32O6S

Molecular Weight

460.58

References & Citations

[1]Gyömber E, et al. Effect of lipoxygenase inhibitors and leukotriene antagonists on acute and chronic gastric haemorrhagic mucosal lesions in ulcer models in the rat. J Gastroenterol Hepatol. 1996 Oct;11 (10) :922-7.|[2]Jacques CA, et al. The contractile activities of lipoxin A4 and lipoxin B4 for guinea-pig airway tissues. Br J Pharmacol. 1988 Oct;95 (2) :562-8.|[3]McMahon TJ, et al. Influence of SQ 30741 on thromboxane receptor-mediated responses in the feline pulmonary vascular bed. J Appl Physiol (1985) . 1991 Nov;71 (5) :2012-8.|[4]Küng CF, et al. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension. 1995 Feb;25 (2) :194-200.